The Foundation for Innovative New Diagnostics (FIND), which is supporting the development and early implementation of diagnostic tests for tuberculosis (TB), malaria, and other diseases of the developing world, has confirmed an extension of its existing development partnership with 42 Technology.
The consultancy has been appointed to work on a number of major new diagnostic projects involving the development of very-low-cost and more-effective tests that are simple and robust enough to be used in challenging locations and closer to patients. The work will primarily benefit detection and screening initiatives for the control and treatment of TB and malaria, diseases that together account for more than two million deaths each year, according to FIND. Additionally, a number of other infectious diseases, such as sleeping sickness, which have traditionally received little attention, are also expected to benefit from this collaboration.
42 Technology will provide a range of product and process development skills: from assessing the feasibility of biological methods to producing prototype devices and proving performance in the real world. Initial work is focused on understanding the needs of existing diagnostic test protocols, with particular consideration for human interaction and how this impacts test performance. Such analysis will help to identify the challenges involved and enable 42 Technology to propose novel tailored solutions.
FIND has been working with 42 Technology for almost four years on a variety of projects including the development of new ways to more easily and safely transfer precise volumes of infected patient sputum, and a novel technique enabling earlier detection of TB by significantly improving the analytic sensitivity of existing diagnostic tests.